secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTELLIGENT BIO SOLUTIONS INC. (INBS)
CIK:        0001725430
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0001493152-25-005244
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INBS preliminary Q2 revenue $0.61M; six-month gross profit up 32.6% to $0.57M, margin 38.5%
--------------------------------------------------------------------------------

- Unaudited revenue $0.61M for Q2, $1.48M for six months ended Dec 31, 2024.
- Gross profit for six months increased 32.6% to $0.57M; gross margin expanded to 38.5% from 27.7%.
- Higher-margin cartridge sales driving profitability; 400+ active accounts.
- FDA 510(k) submitted for fingerprint drug screening system to enter U.S. market in 2025.
- Calendar 2024 revenue grew 23% year-on-year; expects to file 10-Q in week of Feb 10.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725430/000149315225005244/0001493152-25-005244-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725430/000149315225005244/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-005244

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer